Salugen researchers present data at the Annual Meeting of the National Nutritional Foods Association suggesting that consumers tested with the "Sweet Tooth Gene" (Dopamine D2 Receptor Gene) can benefit for DNA-Customized GenoTrim.

San Diego, CA (PRWEB) July 19, 2006 -- Salugen, Inc., a leader in personalized healthcare, presented early findings from the D.I.E.T. Study (Dutch Investigation to Evaluate Treatments of DNA-Customized Nutritional Solutions for Weight Management) this past weekend at the annual meeting of the National Nutritional Foods Association (NNFA) in Las Vegas, during the scientific poster session on Friday afternoon. This data suggests that consumers with the “Sweet Tooth Gene” are 1.4 times more likely to suffer from weight problems and those consumers may benefit from DNA-customized GenoTrim (www.genotrim.com).

In a study of 901 subjects entitled, “Dopamine D2 receptor gene polymorphisms are significantly associated with percentage body fat and obesity in the D.I.E.T. Study: a functional basis for the nutrigenomic response of chromium picolinate (CrP) in producing body composition effects,” Salugen Chief Scientific Officer and Adjunct Professor at Wake Forest University School of Medicine, Dr. Kenneth Blum, presented early findings suggesting the need to genotype obese subjects for the “Sweet Tooth Gene” (Dopamine De Receptor Gene) prior to chromium picolinate nutritional supplementation as a treatment modality resulting in weight loss.

      To read the rest of this release, click here.